Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.
Antineoplaston therapy is an experimental approach to cancer treatment that uses chemical compounds called antineoplastons. These compounds are made up of amino acids and small chains of amino acids called peptides. Originally found in normal human blood and urine, antineoplastons are now produced in laboratories for research purposes. The therapy was developed by Dr. Stanislaw Burzynski in the 1970s and is offered mainly at his clinic. Despite being promoted as a cancer treatment, antineoplaston therapy is not approved by the U.S. Food and Drug Administration (FDA) for any disease, including cancer.
Patients with cancer may hear about antineoplaston therapy when exploring all possible treatment options, especially if standard treatments have limited success or if they are interested in clinical trials or alternative therapies. Understanding this therapy helps patients and caregivers recognize that it is still under study and has not been proven safe or effective through large, well-designed clinical trials. The therapy’s experimental status means it carries uncertainties about benefits and risks, including serious side effects such as neurological problems.
When researching cancer treatments, patients might find information about antineoplaston therapy on clinical trial listings, alternative medicine websites, or through discussions with healthcare providers. The therapy may be described as a way to fight cancer cells, support the immune system, or improve quality of life, but these claims are not backed by strong scientific evidence. Some patients have reported side effects like confusion, seizures, and swelling near the brain. Because of these risks and the lack of FDA approval, it is important to approach this therapy cautiously.
The term antineoplaston therapy might appear in medical reports, treatment plans, or clinical trial information, especially if a patient is considering or participating in experimental treatments. It is not part of routine cancer care and is usually mentioned only when patients or doctors discuss clinical trials or alternative options. The therapy is sometimes studied alongside standard treatments, making it hard to know which effects come from antineoplastons versus other therapies.
Hearing about antineoplaston therapy does not mean the treatment is proven to work, safe, or approved by regulatory agencies like the FDA. It is not a standard cancer treatment, nor is it widely recommended or covered by insurance. The presence of the term in a discussion or report does not guarantee that a patient will receive this therapy or that it will be effective. The fact that antineoplastons are derived from natural substances does not ensure they are free from risks or side effects.
If you hear about antineoplaston therapy, consider asking your care team: What evidence supports this treatment for my cancer type? Are there any approved clinical trials I could join? What are the known risks and side effects? How might this therapy interact with my current treatments? What are safer, more established alternatives? These questions can help you understand whether this therapy fits your care plan and what to expect.
Antineoplaston therapy remains experimental and is not approved by the FDA. Some patients have experienced serious side effects, including neurological problems. Because of this, it should only be considered within carefully controlled clinical trials or with full awareness of the risks. It is important never to replace standard cancer treatments with unproven therapies without thorough discussion with your medical team. Staying informed and cautious helps ensure the safest and most effective care decisions.
If antineoplaston therapy comes up during your cancer journey, the best step is to talk openly with your healthcare providers. They can explain the current research, risks, and benefits, and guide you toward treatments that have been proven to work. If you are interested in clinical trials, your care team can help you find legitimate studies suitable for your condition. Being well-informed and asking questions will help you make the best choices for your care and avoid false hope or unnecessary risks.
Public source information used for this glossary entry includes: